Male Hypogonadism: Global Prevalence and Trends

How Common Is Male Hypogonadism?

Prevalence estimates range from 2 percent to 40 percent of adult men, and that wide range reflects genuine disagreement about where to set the diagnostic threshold for total testosterone. Studies using 300 ng/dL as the lower limit of normal consistently report higher prevalence than those using 200 ng/dL. The 2018 Endocrine Society Clinical Practice Guideline formally recommends confirming two morning total testosterone values below 300 ng/dL before labeling a man hypogonadal [1].

Population-Level U.S. Data

The Massachusetts Male Aging Study (MMAS), which followed 1,709 men aged 40 to 70 in the Boston area, found that age-adjusted androgen deficiency in the aging male (ADAM) affected approximately 12.3 percent of participants at baseline, rising sharply with each decade of life [2]. A separate analysis using National Health and Nutrition Examination Survey (NHANES) data estimated that roughly 4.5 million U.S. Men aged 30 to 79 meet biochemical criteria for hypogonadism [3].

The Age Gradient

Age is the single strongest predictor of low testosterone in otherwise healthy men. The Baltimore Longitudinal Study of Aging documented that biochemical hypogonadism (total testosterone <325 ng/dL) affected approximately 12 percent of men in their forties, 19 percent in their fifties, 28 percent in their sixties, and over 49 percent of men aged 70 to 79 [4]. That gradient exists even after adjusting for body mass index and comorbid illness.

International Estimates

European and Australian cohort studies report broadly similar figures. The European Male Ageing Study (EMAS), which enrolled 3,369 men aged 40 to 79 across eight countries, found that 2.1 percent met a strict symptomatic plus biochemical definition (total testosterone <11 nmol/L plus three sexual symptoms), while up to 17 percent met biochemical criteria alone [5]. The strict symptomatic definition yields lower numbers; biochemical-only definitions yield higher ones.

Secular Trends: Are Testosterone Levels Falling Over Time?

Population testosterone levels appear to be declining over time in a way that cannot be explained by aging alone. This is among the most discussed findings in reproductive endocrinology over the past two decades.

The Travison 2007 Analysis

Travison and colleagues published a landmark analysis in the Journal of Clinical Endocrinology and Metabolism examining three separate cross-sectional cohorts of Massachusetts men sampled in 1987 to 1989, 1995 to 1997, and 2002 to 2004 [6]. Men born in later decades had lower testosterone than men of the same age born earlier. Mean total testosterone declined approximately 1.2 percent per year over that period, independent of age, BMI, smoking status, and alcohol use. The authors estimated that a 65-year-old man in 2002 had testosterone levels roughly 15 percent lower than a 65-year-old man in 1987.

Confirming Evidence From Other Cohorts

A Danish study of men referred for semen analysis found similar generation-on-generation declines [7]. Finnish population data from the Health 2000 and Health 2011 surveys showed a statistically significant drop in mean serum testosterone over the 11-year interval, with the steepest decline in men under age 50 [8]. These findings align with concurrent data showing rising rates of obesity, type 2 diabetes, and sedentary behavior, all of which suppress the hypothalamic-pituitary-gonadal (HPG) axis.

What Is Driving the Decline?

No single mechanism explains the secular trend fully, but several contributors are well-supported. Adipose tissue converts testosterone to estradiol via aromatase, so rising obesity rates directly suppress circulating testosterone. Sleep-disordered breathing, which has grown in parallel with obesity, blunts the nocturnal LH pulse that drives morning testosterone peaks [9]. Environmental endocrine disruptors including phthalates and bisphenol A have been proposed as additional contributors, though causality in humans remains unconfirmed [10].

Risk Factors Shaping Global Prevalence

Hypogonadism is not randomly distributed. Several modifiable and non-modifiable factors cluster in affected men.

Obesity and Metabolic Syndrome

The relationship between adiposity and low testosterone is bidirectional and well-replicated. Cross-sectional NHANES data show men with a BMI above 40 have mean total testosterone values roughly 30 to 40 percent below those of normal-weight men [3]. Visceral fat in particular correlates with elevated estradiol, which feeds back to suppress LH and FSH. The Endocrine Society's 2018 guideline explicitly states: "We suggest against making a diagnosis of androgen deficiency in men with acute or subacute illness, or in men with obesity or medical conditions that lower testosterone but are potentially reversible" [1].

Type 2 Diabetes

Men with type 2 diabetes have approximately twice the odds of biochemical hypogonadism compared to euglycemic men of the same age and BMI. A meta-analysis by Dhindsa and colleagues pooled data from multiple studies and found that roughly 25 to 50 percent of men with type 2 diabetes have total testosterone below 300 ng/dL [11]. The mechanism involves both direct suppression of GnRH pulsatility and reduced SHBG, which complicates interpretation of total testosterone.

Age and Comorbidity Load

Age interacts with every other risk factor. A man aged 65 with type 2 diabetes, obesity, and obstructive sleep apnea carries a dramatically higher probability of hypogonadism than a healthy 65-year-old. The EMAS identified the combination of sexual dysfunction symptoms with confirmed biochemical deficiency as most prevalent in men with three or more chronic conditions [5].

Geographic and Ethnic Variation

Direct cross-national comparisons are limited by assay heterogeneity, but available data suggest East Asian men have modestly higher mean testosterone in some surveys, possibly reflecting lower average BMI. A comparison of Korean and U.S. NHANES data found Korean men aged 40 to 69 had mean total testosterone approximately 10 to 15 percent higher than age-matched U.S. Men, though the studies used different assay platforms [12]. This finding requires cautious interpretation.

Diagnosis Rates Versus True Prevalence: A Persistent Gap

Despite high estimated prevalence, hypogonadism remains substantially underdiagnosed and undertreated. A claims-database analysis of over 6.6 million U.S. Men found that fewer than 12 percent of men who likely met biochemical criteria had an ICD code for hypogonadism in their records [13]. Several barriers drive this gap.

Symptom Overlap and Attribution

Low libido, fatigue, and depressed mood, the most common presenting symptoms, are also common in depression, sleep disorders, and primary care in general. Clinicians often attribute these symptoms to aging or psychosocial stress before ordering testosterone testing. The AUA and Endocrine Society recommend testing any man who presents with consistently low sexual desire, erectile dysfunction, decreased energy, or loss of muscle mass alongside other suggestive features [1].

Assay Variability

Total testosterone assays vary substantially across platforms. Immunoassay-based methods used in most community labs can misclassify borderline-low values. The Endocrine Society's guideline specifically recommends liquid chromatography-tandem mass spectrometry (LC-MS/MS) for accurate measurement, particularly in men near the diagnostic threshold [1]. The CDC's Hormone Standardization (HoSt) program has worked to reduce inter-laboratory coefficient of variation, which historically exceeded 20 percent for testosterone immunoassays [14].

Single-Measurement Insufficiency

Because testosterone is pulsatile and diurnal, a single low value can reflect transient suppression. The 2018 Endocrine Society guideline and the 2022 AUA testosterone deficiency guidelines both require two separate morning measurements before confirming diagnosis [1, 15]. Many primary care workups stop after one value, leading to both over- and underdiagnosis.

Global Burden Projections and Trends Looking Forward

If secular testosterone decline continues at the rates documented through 2004, and if global obesity prevalence continues its current trajectory per WHO data, epidemiological models project a meaningful increase in absolute hypogonadism burden over the next two decades [16].

Aging Populations

Men aged 65 and older represent the fastest-growing demographic in North America, Europe, Japan, and South Korea. Given the steep age gradient in testosterone, an older male population translates directly into more hypogonadal men in absolute terms even without any worsening of secular trends.

Rising Obesity in Low- and Middle-Income Countries

Obesity is rising fastest in countries that previously had low rates, including parts of sub-Saharan Africa, South Asia, and Latin America [17]. As BMI distributions shift upward in these populations, hypogonadism prevalence is likely to follow. Surveillance data from these regions remain sparse.

The Testosterone Therapy Market as a Proxy Signal

Testosterone replacement therapy prescriptions in the U.S. Tripled between 2001 and 2011, reaching approximately 5.3 million prescriptions annually before declining somewhat after FDA safety communications in 2014 and 2015 regarding cardiovascular risk [18]. That trajectory reflects both increasing diagnosis and likely some degree of overtreatment. The FDA required label updates for all approved testosterone products in 2015 to clarify that approval is limited to classical hypogonadism (primary or secondary) and not age-related decline alone [18].

Clinical Definitions and Guideline Thresholds

Definitions differ across societies, and these differences directly affect reported prevalence.

Endocrine Society 2018

The Endocrine Society's Clinical Practice Guideline defines hypogonadism as a clinical syndrome combining symptoms and signs of androgen deficiency with a biochemical deficit: two morning total testosterone values <300 ng/dL confirmed by a reliable assay [1]. Free testosterone measurement is recommended when total testosterone is borderline (300 to 400 ng/dL) or when SHBG abnormality is suspected.

AUA 2022

The American Urological Association's 2022 guideline on testosterone deficiency similarly sets the threshold at <300 ng/dL for total testosterone, with the addition that clinicians should use a validated symptom questionnaire alongside biochemical confirmation [15]. The AUA guideline states: "Testosterone deficiency is defined as total testosterone <300 ng/dL on at least two separate occasions measured in the morning."

EAU and ISSAM

The European Association of Urology and the International Society for the Study of the Aging Male use slightly different thresholds in their guidance documents, with some recommending a lower bound of 8 to 12 nmol/L (roughly 230 to 346 ng/dL depending on conversion) and emphasizing symptomatic assessment as equally important to biochemical confirmation [19].

What Epidemiology Tells Clinicians

The data carry several direct clinical implications worth making explicit.

A man presenting with fatigue and low libido has a non-trivial prior probability of biochemical hypogonadism, especially if he is over 50, carries excess adiposity, or has type 2 diabetes. Two fasting morning testosterone measurements drawn before 10 a.m. Via a mass spectrometry-validated assay are the minimum workup before ruling hypogonadism in or out.

Population-level testosterone decline means age-matched reference ranges from older studies may not be appropriate comparators. Clinicians should use contemporary laboratory reference intervals derived from healthy young men, which is the approach endorsed by the Endocrine Society [1].

Reversible contributors must be addressed before initiating testosterone replacement. Weight loss of 10 percent body weight can raise total testosterone by 60 to 100 ng/dL in obese hypogonadal men, as shown in a randomized trial by Grossmann and colleagues published in the European Journal of Endocrinology [20]. That improvement may bring borderline-hypogonadal men above the treatment threshold without exogenous hormone use.